CANTICANTI home
Back to diseases

Disease hub

Breast cancer

Open Targets catalogue label: breast cancer

Breast malignancy bucket — structured evidence and trial mirrors when rows exist. Requires oncology review.

Data: Live structured evidence (Supabase)

Source catalogue
17180
Imported rows
—
Explorer-eligible
—
Targets w/ drugs
—
Open guided lookup (general disease context)
Also indexed as

mammary carcinoma · BC · breast cancer · MONDO_0007254 · malignant neoplasm of the breast · malignant tumor of breast · malignant tumour of breast · mammary cancer · malignant breast tumor · malignant tumour of the breast · malignant tumor of the breast · cancer of breast · malignant neoplasm of breast · malignant breast neoplasm · malignant breast tumour · mammary neoplasm · primary breast cancer · breast tumour · mammary tumour · breast tumor · mammary tumor · NCIT:C9335 · ICD10CM:C50 · DOID:1612 · MEDGEN:651 · SCTID:254837009 · ICD9:174.8 · UMLS:C0006142

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible

Important limitations

  • Shared-target cross-indication paths show mechanistic adjacency only — they do not establish clinical benefit or recommend treatment.
  • Disease→target associations are scoped to this hub’s Open Targets umbrella concept; subtype evidence may be represented on separate catalogue pages.
Disease–target coverage
Coverage metrics for this hub when live evidence-graph and catalogue snapshots are available.
Source catalogue associations
17,180

Open Targets associated-target catalogue count for this disease node — not clinically ranked, validated, or treatment-linked targets.

Measured from Open Targets on 2026-05-15

Imported evidence rows
—

Source evidence rows, not unique targets.

Explorer-eligible targets
—

Targets in the GBM evidence-graph view with default dashboard eligibility.

Targets with drug relationships
—

Distinct active GBM explorer-eligible targets with drug–target mechanism-of-action relationships (disease-scoped; not a global catalogue count).

Disease-linked drugs
—

Unique active drugs linked to this disease in the evidence graph.

Disease-drug evidence edges
—

Active disease–drug evidence edges (methodology detail).

Catalogue and row counts are research inventory signals. They do not mean every association is clinically relevant, validated, druggable, or treatment-linked.

Disease-aware regulatory approval

Regulator-backed indication status for Breast cancer. Trial phase is not approval.

No regulator-backed approval indication was resolved in Canti for the sampled drugs.

Currently indexed off-label and cross-indication drug evidence

Complete paths only — grouped by drug.

Showing 100 of 159 complete cross-indication paths · 10 of 44 drugs shown

10 of 44 drugs

10 of 44 drugs

Approval in another disease and a shared target or biomarker do not establish safety or clinical benefit in Breast cancer.